.png)
Austin, TX (March 11, 2025) – Prodigy Health is pleased to announce the availability of HYMPAVZI™ (marstacimab-hncq) by Pfizer, an innovative tissue factor pathway inhibitor (TFPI) designed for routine prophylaxis in adults and adolescents (12 years and older) with hemophilia A or B without inhibitors. HYMPAVZI™ joins Prodigy’s broad suite of products for hemophilia patients.
With a commitment to advancing specialty pharmaceutical access through cutting-edge technology and a patient-first approach, Prodigy Health is proud to distribute this innovative therapy that redefines bleeding disorder management. HYMPAVZI™ provides a novel treatment option with once-weekly subcutaneous administration, reducing the need for traditional factor replacement therapies.
“Prodigy Health remains dedicated to ensuring that providers and patients have access to the most advanced and effective therapies available,” said Keith Patek, President at Prodigy Health. “The launch of HYMPAVZI™ represents an important step forward in treating hemophilia A and B, offering a more seamless and efficient approach to managing these conditions.”
The introduction of HYMPAVZI™ reinforces our commitment to delivering transformative therapies that enhance patient care and provider support.
For more information on HYMPAVZI™ availability and ordering through Prodigy Health, please visit prodigyhealth.com or call 877-693-4376.
About Prodigy Health
Founded in 2001 in Austin, TX, Prodigy Health is an independent specialty pharmaceutical distributor dedicated to transforming healthcare supply chains with cutting-edge technology, innovative solutions, and a fun-loving, human-centered approach. By blending efficiency, compassion, and clever problem-solving, Prodigy Health makes pharmaceutical access seamless and impactful for healthcare providers and their patients.
Media Contact:
Faith Kouadio
fkouadio@prodigyhealth.com
Prodigy Health | http://www.prodigyhealth.com
